The Cigna (CI) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

The Cigna

NYSE•Healthcare•Healthcare Plans

$276.00-4.45(-0.02%)Pre-market

Market Cap

$280.45

P/E

0.0x

P/S

0.0x

P/B

0.0x

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. It operates through two segments: Evernorth Health Services and Cigna Healthcare. The Evernorth Health Services segment includes Pharmacy Benefit Services and Specialty and Care Services, offering pharmacy benefit management, drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management, pharmacy benefits, home delivery pharmacy, specialty pharmacy, specialty pharmaceutical distribution, and clinical programs for whole-person health outcomes. The Cigna Healthcare segment comprises U.S. Healthcare and International Health, delivering comprehensive medical and coordinated solutions such as employer medical plans, individual and family plans, behavioral health, consumer health engagement, dental, pharmacy management, stop-loss insurance, global health care, and local health care solutions, as well as health care benefits for mobile individuals and employees of multinational organizations. The company offers other operations, including corporate-owned life insurance, reinsurance, and certain run-off and non-strategic businesses. The company distributes its products and services through brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.

How this company scores

GoodMetricSide Score: 70/100

Strongest: Cash & Earnings Quality (23/25); weakest: Profitability (12/25).

Profitability12/25

Growth21/25

Balance Sheet & Red Flags14/25

Cash & Earnings Quality23/25

Strengths

Rising free cash flowRising earningsCash-backed earningsConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 0.0x5y range 0.0x – 0.0x

Currently near its 20-quarter median.

P/S · 0.0x5y range 0.0x – 0.0x

Currently below its 20-quarter median.

P/B · 0.0x5y range 0.0x – 0.0x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Cash Burn

Watch

FCF turned negative in 2 of the last 8 quarters — occasional cash consumption.

Price & Volume

Market Cap $280.45

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $282.38B
Q. Revenue: $71.67B
TTM EBITDA: $12.68B
TTM Op. Income: $9.96B
Q. Op. Income: $2.68B
TTM Net Income: $6.23B
Q. Net Income: $1.66B
EPS: $1.66B
Shares Out.: $1

$282.38B in TTM revenue grew 7.8% YoY, reaching $71.67B last quarter. TTM EBITDA of $12.68B and TTM operating income of $9.96B show growth is flowing through to the bottom line. TTM net income of $6.23B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 88.2%
EBITDA Margin: 4.6%
Op. Margin: 3.7%
Net Margin: 2.3%

Op. margin of 3.7% is up 0.3% YoY — cost efficiency is improving. Net margin at 2.3% and gross margin of 88.2% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 0.0x
P/S Ratio: 0.0x
P/B Ratio: 0.0x

At 0.0x P/E, the stock trades below typical market levels. P/S of 0.0x and P/B of 0.0x provide additional context. P/E sits below typical market levels while revenue is growing. Over the past year, P/E is down 26% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $157.08B
Cash: $6.30B
Long-Term Debt: $29.09B
Book Value: $42.62B
D/E Ratio: 0.7
Debt/EBITDA: 8.7

With $157.08B in assets and $29.09B in long-term debt, D/E is 0.7and book value is $42.62B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-421.00M
TTM Free Cash Flow: $10.28B
FCF Margin: 3.6%
FCF / Net Income: 1.6

TTM FCF of $10.28B on $-421.00M in operating cash flow. The FCF / Net Income ratio of 1.6x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 94% — an improving trend.